Multicenter Retrospective Analysis of 418 Patients LYON, France , March 22, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the publication of a peer-reviewed article that analyzed Ablatherm Robotic HIFU for prostate tissue ablation in patients who
LYON, France , Aug. 22, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at Henry Ford Hospital in Detroit, Michigan , using the Company's FDA-cleared Ablatherm Robotic HIFU.
EDAP's Ablatherm® Robotic HIFU Treatments Performed at University of Minnesota LYON, France , February 27, 2017 -- EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic ultrasound, today announced the first prostate ablation treatments performed at the University of Minnesota , Minneapolis ,
LYON, France , Oct. 22, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its high-intensity focused ultrasound (HIFU) for the treatment of localized prostate cancer, Ablatherm-HIFU, will be featured in multiple presentations
LYON, France, Sep 25, 2008 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that its High Intensity Focused Ultrasound (HIFU) technology was highlighted at the City of Hope Second Annual Conference on New Technologies
Four Scientific Sessions Highlighted HIFU for Treatment of Prostate Cancer HIFU Featured in Plenary Lecture and Two Moderated Posters at Engineering and Urology Society Meeting Significant Interest in both HIFU and ESWL Technologies at EDAP Booth LYON, France , May 14, 2013 (GLOBE NEWSWIRE) -- EDAP